Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: Implications for clinical immunogene therapy of cancer

Cancer Gene Therapy

Volumn 13, Issue 5, 2006, Pages 503-509

  Lamers, C H J ^a   Willemsen, R A ^a   Van Elzakker, P ^a   Van Krimpen, B A ^a   Gratama, J W ^a   Debets, R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clinical study; Human T lymphocytes; Immunogene therapy; Packaging cell line phoenix; Renal cell carcinoma; Single chain chimeric receptor

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR; RETROVIRUS VECTOR; SCFV(G250) CHIMERIC RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER GENETICS; CANCER THERAPY; CELL DIFFERENTIATION; CHIMERA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOGENETICS; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TRANSGENE;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL LINE; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; GENE THERAPY; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS; RECEPTORS, IMMUNOLOGIC; RETROVIRIDAE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRUS ASSEMBLY;

ANIMALIA; GIBBON APE LEUKEMIA VIRUS;

EID: 33645873884     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700916     Document Type: Article

References (11)

1. Lamers CH, Willemsen RA, Luider BA, Debets R, Bolhuis RL. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther 2002; 9: 613-623.
2. Weijtens ME, Willemsen RA, Hart EH, Bolhuis RL. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Therapy 1998; 5: 1195-1203.
3. Weijtens ME, Hart EH, Bolhuis RL. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Therapy 2000; 7: 35-42.
4. Le Doux JM, Morgan JR, Yarmush ML. Differential inhibition of retrovirus transduction by proteoglycans and free glycosaminoglycans. Biotechnol Prog 1999; 15: 397-406.
5. Swift S, Lorens J, Achacoso P, Nolan GP. Radid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-basd systems. Current Protocols in Immunology 1999; 10.17: 14-29.
6. Kustikova OS, Wahlers A, Kuhlcke K, Stahle B, Zander AR, Baum C et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003; 102: 3934-3937.
7. Schaft N, Willemsen RA, de Vries J, Lankiewicz B, Essers BW, Gratama JW et al. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol 2003; 170: 2186-2194.
8. Baum C, Von Kalle C, Staal FJ, Li Z, Fehse B, Schmidt M et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004; 9: 5-13.
9. Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003; 9: 367-369.
10. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999; 162: 2227-2234.
11. Lamers CHJ, Sleijfer S, Willemsen RA, Debets R, Kruit WHJ, Gratama JW et al. Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes. J Biol Reg Homeost Agents 2004; 18: 134-140.